TOP TALENT FROM DIVERSE BACKGROUNDS

Board of Directors

Masayuki Kobayashi
PRESIDENT & REPRESENTATIVE DIRECTOR
Taiho Pharmaceutical Co., Ltd.
In April 2012, Mr. Kobayashi was appointed President & Representative Director of Taiho Pharmaceutical Co. Since 1993, he has taken on various roles at Taiho, working in both clinical research and sales. From 2002 to 2010, Mr. Kobayashi launched Taiho Pharma USA, Inc., as President and CEO of the company. He went on from there to serve as President and CEO of Otsuka America, Inc. from June 2010 to March 2012. Masayuki Kobayashi graduated from Gakushuin University in 1989.
Eric Benn
President & CEO
Taiho Oncology, Inc.
Eric Benn was appointed President and Chief Executive Officer of Taiho Oncology, Inc. in 2010, following 2 years as Chief Operating Officer of Taiho Pharma USA. Before joining Taiho, he served as a strategic consultant to the President of Taiho from 2007 to 2009. Mr. Benn has over 30 years of experience in the Pharmaceutical industry, which includes founding a private pharmaceutical consulting practice, as well as 21 years at Bristol-Myers Squibb, where he held various executive leadership positions in Australia, Canada and the USA. During his career, Mr. Benn has been directly involved in the preparation for and launch of more than 15 products across 5 therapeutic areas, including oncology. He received a Bachelor of Commerce degree from the University of Windsor in Ontario, as well as a Bachelor of Science degree in Biology/Microbiology from the University of Western Ontario in London, Ontario.

EXECUTIVE LEADERSHIP TEAM

Taiho Oncology executive leadership team members are made up of industry leaders from both Japan and the United States. Each member possesses a deep understanding of the pharmaceutical industry, along with a proven track record in clinical research, product development, sales and marketing, and corporate governance.

Masayuki Kobayashi
PRESIDENT & REPRESENTATIVE DIRECTOR
Taiho Pharmaceutical Co., Ltd.
In April 2012, Mr. Kobayashi was appointed President & Representative Director of Taiho Pharmaceutical Co. Since 1993, he has taken on various roles at Taiho, working in both clinical research and sales. From 2002 to 2010, Mr. Kobayashi launched Taiho Pharma USA, Inc., as President and CEO of the company. He went on from there to serve as President and CEO of Otsuka America, Inc. from June 2010 to March 2012. Masayuki Kobayashi graduated from Gakushuin University in 1989.
Eric Benn
President & CEO
Taiho Oncology, Inc.
Eric Benn was appointed President and Chief Executive Officer of Taiho Oncology, Inc. in 2010, following 2 years as Chief Operating Officer of Taiho Pharma USA. Before joining Taiho, he served as a strategic consultant to the President of Taiho from 2007 to 2009. Mr. Benn has over 30 years of experience in the Pharmaceutical industry, which includes founding a private pharmaceutical consulting practice, as well as 21 years at Bristol-Myers Squibb, where he held various executive leadership positions in Australia, Canada and the USA. During his career, Mr. Benn has been directly involved in the preparation for and launch of more than 15 products across 5 therapeutic areas, including oncology. He received a Bachelor of Commerce degree from the University of Windsor in Ontario, as well as a Bachelor of Science degree in Biology/Microbiology from the University of Western Ontario in London, Ontario.
Tim Whitten
Senior Vice President & Chief Commercial Officer
Taiho Oncology, Inc.
Tim Whitten was appointed Taiho Oncology, Inc.’s Senior Vice President & Chief Commercial Officer in February 2013. Prior to joining Taiho, Mr. Whitten served as President and CEO of Transave/lnsmed from 2006 to 2012. During this time he guided the company’s lead product from the preclinical stage into a global phase 3 program. In 2010, he took the private company, Transave, into the public marketplace via a merger with lnsmed, a company traded on the NASDAQ. From 2001 to 2006, Mr. Whitten was employed by Pharmacyclics, where he served in various roles, including Senior Vice President, Marketing & Sales, and Business Development. Mr. Whitten spent 17 years at Bristol-Myers Squibb, where he served in various sales, marketing, and strategic planning roles, including Vice President, Marketing, for the U.S. Oncology and Immunology Franchise and Vice President, Global Marketing, Oncology, Immunology, and Pulmonary Diseases. Among his accomplishments, including several product launches, he directed the successful introduction of TAXOL into the U.S. oncology market. Mr. Whitten graduated from West Virginia University in 1980 with a Bachelor of Science in Pharmacy and also went on to graduate from the University of Virginia with a Master of Business Administration in 1985.
Dr. Vojo Vukovic, MD, PhD
Chief Medical Officer
Taiho Oncology, Inc.
Dr. Vojo Vukovic, MD, PhD, was appointed Chief Medical Officer of Taiho Oncology, Inc. in February 2016. Dr. Vukovic has over 20 years of academic and industry experience in oncology research and drug development. Prior to joining Taiho, Dr. Vukovic was Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals Corp. He also held positions at Pfizer, Bionumerik, Ilex Oncology, Ortho Biotech Canada, and Aventis Pasteur in oncological clinical development and medical affairs. Dr. Vukovic received his medical degree from the University of Sarajevo, Bosnia and Hercegovina in 1992, then completed a cancer research fellowship at the West German Cancer Center in Essen, Germany. He subsequently completed graduate training in tumor cell biology, earning MSc (1999) and PhD (2001) degrees at the University of Toronto.
Shigeru Takagi
Executive Director
Clinical Development Division
Medical Affairs Division
Taiho Pharmaceutical Co., Ltd.
Shigeru Takagi is the Head of Clinical Development Division and Head of QA, Regulatory Affairs and Pharmacovigilance Center. During his professional career he has worked in several areas, such as medical affairs, research planning, pharmacovigilance, and clinical development. Mr. Takagi graduated from Okayama University in 1977.
Fabio Benedetti, M.D.
Global Chief Medical Officer
Taiho, Tokyo, Japan
Dr. Fabio Benedetti, MD, was appointed Global Chief Medical Officer in January 2016. Dr. Benedetti has extensive experience in oncology, ranging from medical practice to clinical drug development and medical affairs. Prior to joining the company, he has served in various leadership positions including Senior Vice President and Chief Medical Officer of Oncology at Geron Corporation, Vice President of Medical Affairs at Onyx as well as Millennium Pharmaceuticals, and has held Medical Director level positions at Bristol-Myers Squibb and Roche Laboratories. Dr. Benedetti graduated from Brown University, where he also went on to receive his medical degree in 1990. After finishing his Internal Medicine residency at Strong-Memorial Hospital in Rochester, NY, he went on to complete a Medical Oncology/Hematology fellowship at the Memorial Sloan-Kettering Cancer Center in New York City, where he subsequently worked as an Attending Physician for the Gastrointestinal Oncology Service.
Teruhiro Utsugi, Ph.D.
Executive Director
Discovery & Preclinical Research Division
Strategic Early Development Planning Dept.,
Business Development
Intellectual Property, Legal Affairs
Taiho Pharmaceutical Co., Ltd.
Dr. Teruhiro Utsugi joined Taiho in 1991 and has held several positions in the R&D and Business Development Divisions. Prior to this, he spent 4 years as a scientist at SmithKline French Laboratories and M.D. Anderson Cancer Center in the U.S., and brought with him a vast knowledge in product research. Dr. Utsugi received his bachelor’s and master’s degrees from the University of Nagasaki, and went on to receive his doctorate in Nutrition Science from the University of Tokushima in 1987.

U.S. Leadership Team

Taiho Oncology’s U.S. leadership team brings strong leadership to the North American marketplace, while staying true to Taiho’s legacy of developing the highest quality pharmaceuticals that improve the lives of people everywhere.

Eric Benn
President & CEO
Taiho Oncology, Inc.
Eric Benn was appointed President and Chief Executive Officer of Taiho Oncology, Inc. in 2010, following 2 years as Chief Operating Officer of Taiho Pharma USA. Before joining Taiho, he served as a strategic consultant to the President of Taiho from 2007 to 2009. Mr. Benn has over 30 years of experience in the Pharmaceutical industry, which includes founding a private pharmaceutical consulting practice, as well as 21 years at Bristol-Myers Squibb, where he held various executive leadership positions in Australia, Canada and the USA. During his career, Mr. Benn has been directly involved in the preparation for and launch of more than 15 products across 5 therapeutic areas, including oncology. He received a Bachelor of Commerce degree from the University of Windsor in Ontario, as well as a Bachelor of Science degree in Biology/Microbiology from the University of Western Ontario in London, Ontario.
Tim Whitten
Senior Vice President & Chief Commercial Officer
Taiho Oncology, Inc.
Tim Whitten was appointed Taiho Oncology, Inc.’s Senior Vice President & Chief Commercial Officer in February 2013. Prior to joining Taiho, Mr. Whitten served as President and CEO of Transave/lnsmed from 2006 to 2012. During this time he guided the company’s lead product from the preclinical stage into a global phase 3 program. In 2010, he took the private company, Transave, into the public marketplace via a merger with lnsmed, a company traded on the NASDAQ. From 2001 to 2006, Mr. Whitten was employed by Pharmacyclics, where he served in various roles, including Senior Vice President, Marketing & Sales, and Business Development. Mr. Whitten spent 17 years at Bristol-Myers Squibb, where he served in various sales, marketing, and strategic planning roles, including Vice President, Marketing, for the U.S. Oncology and Immunology Franchise and Vice President, Global Marketing, Oncology, Immunology, and Pulmonary Diseases. Among his accomplishments, including several product launches, he directed the successful introduction of TAXOL into the U.S. oncology market. Mr. Whitten graduated from West Virginia University in 1980 with a Bachelor of Science in Pharmacy and also went on to graduate from the University of Virginia with a Master of Business Administration in 1985.
Dr. Vojo Vukovic, MD, PhD
Chief Medical Officer
Taiho Oncology, Inc.
Dr. Vojo Vukovic, MD, PhD, was appointed Chief Medical Officer of Taiho Oncology, Inc. in February 2016. Dr. Vukovic has over 20 years of academic and industry experience in oncology research and drug development. Prior to joining Taiho, Dr. Vukovic was Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals Corp. He also held positions at Pfizer, Bionumerik, Ilex Oncology, Ortho Biotech Canada, and Aventis Pasteur in oncological clinical development and medical affairs. Dr. Vukovic received his medical degree from the University of Sarajevo, Bosnia and Hercegovina in 1992, then completed a cancer research fellowship at the West German Cancer Center in Essen, Germany. He subsequently completed graduate training in tumor cell biology, earning MSc (1999) and PhD (2001) degrees at the University of Toronto.
Kit Ford
Vice President, Human Resources
Taiho Oncology, Inc.
Kit Ford was appointed our Vice President, Human Resources in January 2014. Prior to joining the company, Ms. Ford spent her career creating HR best practices to ensure the achievement of strategic corporate initiatives, while serving as an advisor and business partner to the executive leadership of various industry leaders, including Unilever’s manufacturing and supply chain operations and Siemens Medical’s marketing and sales organizations. She recently served as the Vice President of Human Resources for NRG Energy, leading the change management effort responsible for NRG’s successful transition from bankruptcy to becoming a Fortune 300 energy company. Ms. Ford received her B.A. in Industrial/Organizational Psychology from Penn State University, and she completed Western Kentucky University’s master’s program in Organizational Psychology, as well as Cornell University’s Labor Relations program.
Michael Schick
Vice President, Sales & Marketing
Taiho Oncology, Inc.
Michael Schick was appointed our Vice President, Sales and Marketing in July 2013. Prior to joining the company, Mr. Schick was a self-employed consultant to the pharmaceutical industry from January 2013 to June 2013. Prior to that, he served various sales and marketing leadership roles at Allos Therapeutics, including Vice President, Sales and Marketing and Vice President of Marketing from July 2009 to October 2012. While at Allos, Mr. Schick was a member of the executive management team that transformed the organization from a development stage biotech to a commercial stage pharmaceutical company. Prior to that, he served as Associate Vice President, Oncology Marketing at ImClone Systems from October 2007 to July 2009, where he was responsible for the Erbitux (cetuximab injection) franchise across multiple indications. Prior to that, from February 2006 to October 2007, Mr. Schick was Executive Director, Oncology Global Marketing at Amgen Inc., where he was responsible for global marketing activities for Neulasta (pegfilgrastim) and Aranesp (darbepoetin alfa injection). From November 2004 to January 2006, Mr. Schick served as Director, Marketing at Pharmacyclics, Inc. Prior to that, he served in a variety of commercial roles at Bristol-Myers Squibb, including sales, strategic planning, and product management focused on multiple oncology brands, including Taxol (paclitaxel injection) and Paraplatin (carboplatin for injection) and the launch of Erbitux for metastatic colorectal cancer. Mr. Schick earned his B.A. from Villanova University.
Takekazu Aoyama
Vice President, Clinical Development
Taiho Oncology, Inc.
Dr. Takekazu Aoyama was appointed our Vice President, Clinical Development in April 2012. He is a board certified physician with extensive clinical practice experience in surgery and general oncology in the U.S. and Japan, and has broad experience in clinical research in various aspects of drug development. Prior to joining the company, Dr. Aoyama served as Senior Director and Scientific Head of Oncology Business Unit at Sanofi-Aventis, Japan, and Regional Medical Affairs Lead in the Asia/Pacific region from June 2010 to March 2012. From January 2006 to May 2010, he was Medical Director, Clinical Oncology Development at Sanofi-Aventis, U.S. From September 2002 to December 2005, Dr. Aoyama served as Medical Director, Global Medical Affairs and Therapeutic Head in Oncology for Omnicare Clinical Research. From 1996 to 2002, he served as Clinical Research Scientist and Postdoctoral Fellow at Division of Surgical Nutrition, Department of Surgery and subsequently at Division of Medical Oncology, Department of Medicine at Jefferson Medical College of Thomas Jefferson University. Dr. Aoyama received his medical degree and his doctorate in Cardiovascular Electrophysiology at Kanazawa University, Kanazawa, Japan. Dr. Aoyama is an active member of ASCO, AACR, ESMO, JSMO, JSS, and JCA.
Kazuhiko Okamoto
Vice President, Finance
Taiho Oncology, Inc.
Kazuhiko Okamoto was appointed our Vice President, Finance in January 2016. Prior to joining Taiho, he worked for two international semiconductor companies, where he developed functional capabilities and gained international experience through his broad range of responsibilities, including sales, strategic marketing, and finance. Mr. Okamoto is a Certified Public Accountant (not in public practice) for the state of Delaware. He earned a Bachelor of Commerce degree from Doshisha University in Kyoto.

Success!

Job description sent to

Success!

Event sent to

Success!

News Release sent to